Good morning, ladies and gentlemen. Welcome to the Kimball Electronics Fourth Quarter Fiscal 2025 Earnings Conference Call. My name is Darrell, and I will be the facilitator for today's call. All lines have been placed in a listen-only mode to prevent any background noise. After the completion of the prepared remarks from the Kimball Electronics leadership team, there will be a question and answer period. To ask a question, simply press star, then the number one on your telephone keypad. Today's call, August 14, 2025, is being recorded. A replay of the call will be available on the Investor Relations page of the Kimball Electronics website. At this time, I would like to turn the call over to Andy Regrut, Treasurer and Investor Relations Officer. Mr. Regrut, you may begin. Thank you, and good morning, everyone. Welcome to our Fourth Quarter Conference Call. With me here today is Ric Phillips, our Chief Executive Officer, and Jana Croom, Chief Financial Officer. We issued a press release yesterday afternoon with our results for the fourth quarter, and the full fiscal year ended June 30, 2025. To accompany today's call, a presentation has been posted to the Investor Relations page on our company website. Before we get started, I'd like to remind you that we will be making forward-looking statements that involve risk and uncertainty and are subject to our safe harbor provisions as stated in our press release and SEC filings, and that actual results can differ materially from the forward-looking statements. Our commentary today will be focused on adjusted non-GAAP results. Reconciliations of GAAP to non-GAAP amounts are available in our press release. This morning, Ric will start the call with a few opening comments. Jana will review the financial results for the quarter and guidance for fiscal 2026, and Ric will complete our prepared remarks before taking your questions. I'll now turn the call over to Ric. Thanks, Andy, and good morning, everyone. I'm encouraged by the results for the fourth quarter and the solid finish to the fiscal year. Q4 came in better than expectations as sales increased sequentially, margins continued to improve, and working capital management drove our sixth consecutive quarter of positive cash flow, which was used to pay down debt. Our balance sheet is now in a position of competitive strength, with ample liquidity to weather an unpredictable environment while providing dry powder for opportunistic investments. In total, fiscal 2025 was a year of controlling what we could control. I am proud of our team as we made significant progress positioning the company for a return to profitable growth with noteworthy accomplishments, including a record number of wins for future business, a meaningful increase in the number of green customer scorecards, quality ratings at a 15-year high, adjusting the cost structure and aligning the portfolio to demand trends, and intensifying our focus as a medical CMO. The new 300,000 sq ft medical facility in Indianapolis, which we announced last quarter, is an important milestone in this strategy. It provides the space needed to expand our production capabilities beyond traditional printed electronics and circuit board assemblies, encompassing cold chain management, complete device assembly, and precision molded plastics. Our current manufacturing includes medical disposables, single-use surgical instruments, and selected drug delivery devices such as autoinjectors. Additionally, we're looking to expand applications in areas such as cardiology, orthopedics, minimally invasive surgery, and surgical instruments and packaging. The medical market presents a compelling opportunity to diversify revenue and leverage our core strengths as a trusted partner in a complex and regulated industry. We expect fiscal 2026 to be another step forward in this journey, and we anticipate positive top-line growth for the company overall in FY 2027. As we return to growth, better capacity utilization will result in higher margins. Turning now to the fourth quarter, net sales for the company were $381 million, an 8% decline compared to Q4 last year when excluding the Automation, Test & Measurement business that was divested. For the second consecutive quarter, our Medical business grew year- over- year, while the other two verticals we serve reported declines. Sequentially, however, the top line increased 2% compared to Q3. Remember, the third quarter included a $24 million non-recurring consigned inventory sale in the Medical vertical, so the sequential sales for recurring business are even more encouraging than what's at the surface. Sales in Medical were $107 million, up 5% compared to the same period last year, and 28% of total company. The increase in Q4 was driven by a step-up in sales with our largest Medical customer, a welcome reprieve after a long period of decline during the FDA recall. We expect the growth with this customer to continue as we were selected as the sole supplier for the respiratory care final assembly and high-level sssemblies business, with most of the production occurring at our facility in Thailand. Similar opportunities are possible as the population ages, access and affordability to healthcare increases, medical devices get smaller in size and require higher levels of precision and accuracy, and connected drug delivery systems become more common as consumer adoption increases. In general, HLA and finished medical devices are great business for us as the cost of sales is lower and the revenue potential is higher than what is customary with contract manufacturing and EMS. This business increases our stickiness with customers. Next is Automotive, with net sales of $184 million, a 13% decrease compared to the fourth quarter of last year, and 48% of the total company. The decline in Q4 was driven by the electronic braking program that, as previously announced, is no longer being produced in Reynosa as a result of a commercial agreement by the OEM to transfer it to another source. This impact was partially offset by the ramp-up of a similar but separate braking program in Romania. In addition, we continue to carefully monitor the demand for electronic steering systems for EVs, which were lower in the quarter. Finally, Industrial, with net sales of $90 million, down 12% year- over- year when excluding AT&M, and representing 24% of total company sales. We see early signs of stability with climate control systems, but this was offset by broad-based declines in other industrial segments in North America and Europe. Asia was approximately flat in Q4. I'll now ask Jana to provide more detail on the financial results for Q4 and our guidance for fiscal 2026. Jana? Thank you, and good morning, everyone. As Ric detailed, net sales in the fourth quarter were $380.5 million, a 12% decrease year over year, down 8% when excluding AT&M. Foreign exchange had a 1% favorable impact on consolidated sales in Q4. The gross margin rate in Q4 was 8%, a 50 basis point decrease compared to 8.5% in the same period of fiscal 2024, with lower absorption and outcome from reduced year-over-year sales driving the decline in rate. However, representing significant sequential improvement over the course of the fiscal year. Adjusted selling and administrative expenses in the fourth quarter were $10.8 million, a $3.2 million or 23% reduction compared to the $14 million we reported in Q4 last year. The decrease occurred from our cost reduction efforts, reduced bonus expense, and not having AT&M in our portfolio this year versus a full quarter of expense in fiscal 2024. When measured as a percentage of sales, adjusted selling and administrative expenses were 2.8%, a 40 basis point improvement compared to 3.2% in Q4 of fiscal 2024. This is consistent with our commitment to control what we can control. All four quarters in the year were at an adjusted SG&A rate of 3% of sales or lower. Adjusted operating income for the fourth quarter was $19.6 million or 5.2% of net sales, which compares to last year's adjusted results of $22.7 million or 5.3% of net sales. The third consecutive quarter of growth in absolute dollars and as a percentage of net sales. Other income and expense was expense of $3.8 million compared to $6.1 million of expense last year, with interest expense, which was down nearly 50% year- over- year, responsible for the change. The effective tax rate in the fourth quarter was 48.3% compared to 44% in Q4 of fiscal 2024. As you may recall, last year's rate was skewed higher by the impacts of a domestic valuation allowance and the impairment and restructuring charges associated with AT&M. We ended the year with an effective tax rate of 35%, driven by the inclusion of GILTI income, which is subject to U.S. taxation despite being earned by our foreign subsidiaries, and withholding tax related to cash repatriation from our foreign subsidiaries, which is offset by lower interest expense on our borrowings. In fiscal 2026, we expect a tax rate in the low 30%. Adjusted net income in the fourth quarter of fiscal 2025 was $8.4 million or $0.34 per diluted share, compared to adjusted net income in Q4 last year of $9.7 million or $0.38 per diluted share. Turning now to the balance sheet, cash and cash equivalents at June 30, 2025, were $88.8 million. Cash generated by operating activities in the quarter was $78.1 million, our sixth consecutive quarter of positive cash flow. Cash conversion days were 85 days compared to 100 days in Q4 of fiscal 2024 and 99 days last quarter. This represents our lowest CCD in three years, with the decrease this quarter compared to Q3 driven by all components of the calculation, with PDSOH showing the strongest improvement. We see additional opportunity to drive higher levels of cash from our EMS operations while continuing to reduce CCD with new working capital initiatives that will be rolled out in FY 2026. Inventory ended the quarter at $273.5 million, a $23.1 million reduction compared to Q3, and $64.6 million, or 19% lower than a year ago. Capital expenditures in the fourth quarter were $9.6 million. For the full year, CapEx was $33.7 million, primarily to support new product introductions and maintenance needs. Borrowings at June 30, 2025, were $147.5 million, a $31.3 million reduction from the third quarter, and down $147.3 million, or 50% from the beginning of the fiscal year. Short-term liquidity available represented as cash and cash equivalents, plus the unused portion of our credit facilities, totaled $380.5 million at the end of the fourth quarter. We invested $3 million in Q4 to repurchase 162,000 shares. Since October 2015, under our Board Authorized Share Repurchase Program, a total of $103.7 million has been returned to our shareholders by purchasing 6.6 million shares of common stock. We have $16.3 million remaining on the share repurchase program. As Ric mentioned, fiscal 2025 was a year of controlling what we could control, and I am proud of our team's resilience and discipline. We made substantial progress adjusting our cost structure to demand trends throughout the year. We improved our balance sheet with working capital initiatives and aligned the portfolio for future growth expectations. We ended fiscal 2025 with net sales totaling $1.487 billion, the third highest annual revenue total in the 60-year history of the company. Adjusted operating income of $61.3 million, or 4% of net sales, inventory down nearly 20% year- over- year, cash generated by operating activities of $183.9 million, a record result for annual cash flows. CCD at our lowest level in three years, and debt paid down 50% in the fiscal year and at its lowest level in three years. $12 million invested to repurchase 653,000 shares of common stock. Fiscal 2026 will be a year of transition, with net sales in the range of $1.35 billion- $1.45 billion, a 2%- 9% decrease compared to fiscal 2025, adjusted operating income in the range of 4.0%- 4.25% of net sales, compared to 4.1% of net sales in fiscal 2025, and capital expenditures in the range of $50 million- $60 million. To put our sales guidance in perspective, two important events occurred in fiscal 2025 that have been normalized when planning for fiscal 2026. The loss of the braking program in Reynosa will have a $60 million unfavorable impact in the year. In addition, we do not expect another large consigned inventory sale similar to Q3 to occur again. Without these two items, our top line guide is approximately flat year- over- year. We expect modest growth in our medical and industrial businesses, but it will be offset by a decline in automotive. Margins are estimated to be in line with FY25 as we repurpose some of the benefit of the Tampa closure to focus on growing the CMO and our core EMS business. It's important to note that when top line growth returns, enhancements to our cost structure should support margin improvements. Capital expenditures will be heavily weighted towards our new facility in Indianapolis, approximately $30 million, with the balance supporting growth, automation, and maintenance. I'll now turn the call back over to Ric. Thanks, Jana. Before we open the lines for questions, I'd like to share a few thoughts in closing. Our company has always focused on high complexity, high reliability programs, whether it's braking and steering systems in vehicles, motor controls for HVAC systems, or diagnostic and therapeutic equipment in the medical field. The emphasis on quality and reliability is deeply embedded in how we operate across all verticals. Internally, we reference a five 9s reliability standard, 99.999%, as a reflection of the performance and consistency we strive for. The medical CMO aligns well with this objective and our expertise in a highly regulated, highly engineered, complex manufacturing environment. We're approaching our medical CMO strategy with additional steps to position the company for long-term profitable growth. As Jana mentioned, we expect to continue to generate positive cash flow, and we will deploy that capital toward growing the CMO. As we evaluate the medical CMO space, we see opportunity for higher EBITDA margins. Our strategy is to pursue growth with blue-chip customers with long product life cycles and a high degree of visibility. It's not just about adding capabilities. It's about building a scalable platform that supports the work we already do well, creates opportunities for vertical integration, and positions us to take on more of the complex programs that align with our strengths. Drug delivery has been a key area of focus for us. Our capabilities are well established, and with the new Indianapolis facility, we believe we're well positioned to meet current and future customer needs, but we're also committed to pursuing inorganic options to augment this space where it makes strategic sense. Throughout this journey, we will stay true to our guiding principles and continue to be collaborative and team-oriented, set high long-term aspirations, not unrealistic goals, but attainable targets that require stretching, communicate openly and proactively, and remain accountable to our company, to our customers, to each other, and to our shareholders. In closing, I'd like to thank the entire Kimball team for their hard work, focus, and dedication as we build tomorrow together. I've never been more excited about the future of the company. Thank you for your support. Darrell, we would now like to open the lines for questions. Thank you, ladies and gentlemen. Analysts may ask a question at this time by simply pressing star one on your dial pad. You may remove yourself from the queue by pressing star two on your dial pad. We ask that if you are using a speakerphone, you pick up your handset before asking your question. One moment, please, for your first question. Our first questions come from the line of Mike Crawford with B. Riley Securities. Please proceed with your questions. Thank you. Could you remind us, the timing of when the new facility in Indianapolis will be ready, and the potential revenue capacity of that building? Yes, Mike. Thanks for joining us. We are planning the grand opening of that facility in November of this year. We're obviously working on, you know, it was completely empty, new building. We're working on that. At that point, we will start to, you know, get equipment in there and get ready to produce. That facility is at 300,000 sq ft, has a lot of capacity for growth. In addition to that, the way that space is configured, we could expand further from there as needed. We couWd handle hundreds of millions of dollars of business in that facility, depending on, you know, the size of programs that ramp up. While in excess of $500 million. Okay, great. I'm pleased to hear your capital allocation focus on the medical CMO. What about some other directions you've been considering the past year, like industrial adjacencies? Yeah. We continue, Mike, to try to take a really sharp strategic lens to where we're focused. We have been in some interesting discussions in industrial, to your point, which would get us beyond areas that we're currently in. We don't have anything to announce on that front at this point. In automotive, we continue, as you know, to feel that the steering and braking that we've been focused on is a great fit for us and gives us great potential moving forward. We do think it's a combination, obviously, a big ramp-up in the medical CMO, but we see opportunities across all of our verticals. Okay. Thank you. Just one last one from me. It's nice to hear you're sole source for Phillips in Thailand, and I guess that you don't really have that many tariff issues with them given their problems in the U.S. What about tariffs in general for your global footprint? Thank you. Yeah, just a couple of comments on that. One reminder is that for the majority of our business, we are not typically the importer of record, which provides us a little bit of protection. We also have a mindset and approach with our customers that the tariffs are a pass-through. If they hit us, they hit others. The other thing that we've done is just take some no-regrets moves given how uncertain the tariff environment is. We talk to our customers and are clear on the pass-through approach that we expect. We talk to customers proactively about, as you well know, we have a global network. If you want to leverage it in a different way, based on your strategy and how tariffs are affecting you, we're happy to talk about leveraging all of our facilities. We also work to qualify alternative sources of supply in different countries just to provide flexibility depending on which directions those go. That's been our approach. Like everyone else, we wake up in the morning and see what changed. We're trying to be flexible and take that approach. Great, thank you. Thank you. Our next questions come from the line of Derek Soderberg with Cantor Fitzgerald. Please proceed with your questions. Yeah. Hey, everyone. Congrats on the results. Thanks for taking the questions. I want to start with the large Medical customer. You're going to be the sole supplier with final assembly, higher-level assembly, with that customer. Can you remind us what you were doing for the respiratory program the last time? Was it a similar type of arrangement? I was wondering if you can comment on sort of the margin profile change of that program. There is not really a margin profile change from what we were producing with them before. We are just starting to produce for them again, which is a really good sign. It has been a great customer. We were doing high-level full and final assembly for them prior, and there have not really been material changes, really any changes to the contract terms. We are just starting up again, which feels really, really great. Jana, did you say that program was coming out of Thailand, your Thailand facility? Yes, it's coming out of our Thailand facility. Got it. Okay. So the. That's helpful. Let me restate that because what I just said was not entirely correct. We had started off the relationship doing printed circuit board assemblies. We had moved into doing some full and final assembly for them, but they had their own footprint in the U.S. We will be doing full and final assembly for all of their manufacturing now. They won't be doing any of it. It will all be supported by us. There is not a second supplier. It's Kimball solely. Got it. That's great to hear. Jana, while I have you, debt levels here are pretty low. I actually wanted to discuss the cash conversion days, improving quite a bit here. Is there sort of a structural new low for you guys as a company? It sounds like there's some room to improve that. What is changing? Are these initiatives you're taking as a company that's improving this? Is the industry kind of changing? Can you talk about some of those initiatives and how much room you have to continue to improve that number? Thanks. Yeah, that's a great question. I don't know so much that the industry is changing as much as things are a pendulum, right? You had just-in-time inventory, and then COVID hit. Then everybody said, "We want you to carry, you know, a ton of inventory." We said, "That's fine, but you've got to give us carrying costs on the inventory." What you're seeing is more of a return to normal, right? 65 days is too tight, but 100 days is too wide. We're sitting at 85 days now with a goal to get down more towards 75-ish days. There are a variety of things that you can do. You can offer AR factoring programs. You can offer supplier financing programs. It's really about controlling AR and AP days as you think about what that means for your, you know, DSO. PDSOH is much more a function of working with the customer on inventory terms. You know, how much safety stock do we really need to have? Getting better controls over a longer line of sight around production and volume levels, you know, 15 months, 18 months, 24 months out, which has been something that I do believe the industry in total has been challenged yet. Just really getting better about that discipline and partnership with your entire supply chain. Got it. That's super helpful. Thanks, Jana. Thanks, everyone. Thank you. Our next questions come from the line of Anja Soderstrom with Sidoti & Company. Please proceed with your questions. Hi, congratulations on the nice progress here, and thank you for taking my question. In terms of the margin improvement, is that mainly going to be driven by the operating margin then, or? Gross margin, you're going to see improvement, and that's a result of a lot of the restructuring that we've done, capacity utilization efforts, the shutdown of Tampa. We've got controls on the SG&A side and a real discipline there too. There's going to be some investment that we make in order to grow, and I alluded to that on the Q3 call, investments around IT innovation that we need to make, investments in business development that are just going to help shore us up for future growth. As we have more revenue, you know, similar to the question we got about, you know, high-level assemblies and final finished assembly, more revenue translates into better capacity utilization, translates into higher margin, right? That is what you should see once we sort of get past FY 2026. Is that really opening up in a more material way as we begin to grow again? Okay. You still expect the adjusted SG&A to be around 3% of revenue, or? 3.5%. Okay. Our historical, yeah, 3.5%. It won't sustainably stay at three. I think I alluded to that on the 3Q call. Thank you. In terms of you shifting a little bit more focus onto the medical segment, what kind of changes are you making to your sort of sales organization and go-to-market strategy? Yeah, no, it's a great, great question, Anja, and thanks for joining. Yeah, we're making hires in business development, you know, as one straightforward path. As you know, we brought our medical businesses together a year or so ago, and in doing so, really leverages our strong and experienced leaders across the entirety now of that medical vertical. We've also undertaken a pretty comprehensive marketing plan, particularly to support the CMO efforts as we now, you know, have capability to do things at a scale and at a technology level that we weren't able to do before. Yes, we are making big, big investments, as you can imagine, with that new facility on the sales side, to, you know, to put effort around that to drive that business over time. Would you go more heavily into that? Has that changed your sort of competitive, the guys you compete against, or is it still the same? It could have some changes there. What is a great differentiator for us, relative to traditional competitors, is we have the FDA experience and we have the capability to actually handle the drug. From what our customers tell us, that's a big advantage that allows us to be more sticky with them and allows us to play a bigger role in what they're doing as well. Okay. Thank you. I'm just curious, within Indiana, the new facility there, will there be a lot of automation there, and how is that sort of affecting the margins? Yeah, there will absolutely be a lot of automation there. We expect that that CMO segment will be accretive to our margins over time, just because of the characteristics of the space. There will certainly be significant investments in equipment and automation, but we still think that that space sets us up for margin accretion. Okay, thank you. That was all for me. Thank you. Our next questions come from the line of Jaeson Schmidt with Lake Street Capital. Please proceed with your questions. Yes, thanks for taking my questions. Looking at that Medical segment, obviously the customer you called out should be a driver here, but are there other pockets of strength that you're expecting in that segment for this year? Yes. We've actually introduced a number of customers, some we've talked about in the past and some we haven't. We are definitely seeing incremental growth over time in medical beyond that customer. In fact, most of the new customers that we've introduced over the last two years have been in that medical segment. We do see opportunity to expand. We think our capabilities fit well. The shift that we've had over time to full assembly gives us more opportunities, and we've really demonstrated capability there. Okay. That's really helpful. Maybe not even looking at fiscal 2026, but longer term, when you think about sort of driving growth in this business, how are you thinking about prioritizing sort of new customers versus expanding the number of programs at existing customers, or really just kind of hoping that the demand profile of the programs you've already won just improves? Great question. I'd say all the above. The quickest return to growth is the programs that we already won a couple of years ago where the demand has been softer than originally projected comes back. We can't control that, but it certainly can be a short-term driver. Beyond that, we are aggressively hunting new business. We are working very closely, and I feel like our customer relationships across the board are as good as they've ever been with existing customers and new programs coming to us. We think it'll be a combination of all those things. The area where you'll probably see the biggest new customer introduction will be the medical space. Okay, that's really helpful. I'll jump back into queue. Thanks, guys. Thank you. We have reached the end of our question and answer session. With that, ladies and gentlemen, this does now conclude today's conference call. The telephone replay will be available approximately three hours after the conclusion of this event. You can access the replay by dialing eight seven seven six six zero six eight five three or two zero one six one two seven four one five. The replay will be available until August 28, 2025, using access ID 137-550-51. Thanks again for your participation. You may disconnect at this time. Enjoy the rest of your day.